ReviewCurrent psychiatry reports2017
Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
Review in Current psychiatry reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 4 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Patient and provider experiences with opioid use disorder care delivered via telehealth: A systematic mixed-studies review.Drug and alcohol dependence · 2025Pooled it
- Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review.The International journal on drug policy · 2024Pooled it
- Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence.Drug and alcohol dependence · 2021Pooled it
- Slow release oral morphine versus methadone for the treatment of opioid use disorder.BMJ open · 2019Pooled it
- Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial.The American journal on addictions · 2021Trial
- Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial.Journal of addiction medicineTrial
- Real-world comparative effects of slow-release oral morphine vs. methadone on healthcare use for opioid use disorder: A population-based target trial emulation.Addiction (Abingdon, England) · 2026Article
- Self-reported cannabis use to manage opioid withdrawal symptoms and reductions in opioid use among people who use unregulated opioids: a cross-sectional analysis.Journal of cannabis research · 2026Article
- The development of a patient-reported outcome measuring opioid use disorder financial toxicity: Establishing content validity and reliability.Drug and alcohol dependence reports · 2026Article
- Street Pharmacology: The Mechanistic Basis of Clinical Pharmacology Underlying the Microdosing Method of Buprenorphine-Naloxone With a Focus on the Unhoused Population.Journal of clinical pharmacology · 2026Review
- Health Plan Disenrollment and Mortality After Initiation of Medications for Opioid Use Disorder.JAMA psychiatry · 2026Article
- IFN-γ and TLR agonist co-adjuvants enhance the efficacy of a lipid-PLGA hybrid nanoparticle-based oxycodone vaccine.Biomaterials · 2026Article
- "This whole thing is relationship medicine": A qualitative analysis of mobile and street-delivered medication for opioid use disorder in King County, Washington, using RE-AIM.Research square · 2026Article
- Longitudinal Patterns of Dental Health Care Utilization 18 Months Before and 36 Months After Initiation of Index Medications for Opioid Use Disorder.Journal of addiction medicine · 2026Article
- Slow-Release Oral Morphine vs Methadone for Opioid Use Disorder in the Fentanyl Era.JAMA network open · 2026Article
- Navigating opioid use disorder treatment for pregnant and parenting people: composite narratives for policy action.Substance abuse treatment, prevention, and policy · 2026Article
- Factors influencing family physicians' willingness to prescribe opioid agonist therapy using virtual modalities: a qualitative analysis.Frontiers in medicine · 2026Article
- Induction of Medication for Opioid Use Disorder in Primary Care.Journal of the American Board of Family Medicine : JABFM · 2025Article
- Exploring service user and family members' perspective and experiences of alcohol dependence treatment in tertiary care hospital: A qualitative study.Indian journal of psychiatry · 2025Article
- The impact of increased telehealth use on the treatment of substance use disorder during the COVID-19 pandemic.SSM - population health · 2025Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThe recent heroin and prescription opioid misuse epidemic has led to a sharp increase in the number of opioid overdose deaths in the USA. Notwithstanding the availability of three FDA-approved medications (methadone, buprenorphine, and naltrexone) to treat opioid use disorder, these medications are underutilized. This paper provides an update from the recent peer-reviewed literature on barriers to the use of these medications.
findingsThese barriers are interrelated and can be categorized as financial, regulatory, geographic, attitudinal, and logistic. While financial barriers are common to all three medications, other barriers are medication-specific. The adverse impact of the current opioid epidemic on public health can be reduced by increasing access to effective pharmacotherapy for opioid use disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.